Showing results (181-190 of 435) with videos related to
Sort By:
Pageof 44
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical EffectsSpyridoula Vasileiou, Premal D Lulla, Ifigeneia Tzannou, et al.Cytotherapy|January 3, 2016
International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trialsJacques Galipeau, Mauro Krampera, John Barrett, et al.Blood|March 24, 2022
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECsDavid H M Steffin, Ibrahim N Muhsen, LaQuisa C Hill, et al.Blood|September 14, 2013
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 studyConrad Russell Y Cruz, Kenneth P Micklethwaite, Barbara Savoldo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2020
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin LymphomaCarlos A Ramos, Natalie S Grover, Anne W Beaven, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T CellsNatalia Lapteva, Margaret Gilbert, Iulia Diaconu, et al.Texas Heart Institute Journal|September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.American Heart Journal|August 25, 2009
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.JACC. Cardiooncology|January 6, 2021
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA TrialRoberto Bolli, Emerson C Perin, James T Willerson, et al.European Journal of Heart Failure|April 3, 2021
A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trialRoberto Bolli, Raul D Mitrani, Joshua M Hare, et al.Pageof 44